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Extracellular K and its shifts can modify the electrophysiological properties of the resting membrane potential in myocardial cells and influence the generation and conduction of impulses in the heart. 1 During the 1950s, Grumbach et al were the first to report that hypokalemia lowered the fibrillation threshold in isolated rabbit hearts. 2 Afterward, a plethora of studies have demonstrated that hypokalemia is associated with an increased risk of ventricular arrhythmias in patients with acute myocardial infarction (AMI). 3, 4 Based on this evidence, practice guidelines for the management of ST-segment elevation myocardial infarction (STEMI) have recommended the maintenance of serum K levels at >4.0 or even >4.5 mEq/L. 5 However, these guidelines have been questioned due to the fact that they derived from small observational cohorts which were conducted prior to modern treatment of AMI with b-blockers and early reperfusion therapy.
In the present issue of Angiology, Shiyovich et al 6 retrospectively evaluated the association between serum K fluctuations and in-hospital mortality in 10 032 patients with AMI hospitalized during 2002 to 2012. After adjusting for confounding factors, the authors concluded that not only minimal (<3.8 mEq/L) and maximal (4.7 mEq/L) serum K levels but also the combination of peak and nadir K levels along with their fluctuations and their timing increased in-hospital AMI mortality.
Based on these results, Shiyovich et al 6 confirmed the U-shaped relationship between serum K levels and mortality (both short and long term) in patients with AMI, as in previous studies. [7] [8] [9] According to their results, patients with serum K levels ranging from 3.5 to 4.0 mEq/L or less frequently from 4.0 to 4.5 mEq/L exhibited the lowest mortality risk. [7] [8] [9] On the other hand, lower and higher serum K levels, including those within the normal range, were significantly associated with worse outcomes, regardless of K repletion during hospitalization. [7] [8] [9] Hence, these results unsettled the previous guidelines suggesting high serum K levels in the acute phase of AMI.
The exact pathophysiology by which decreased or increased serum K levels deteriorate the prognosis in patients with AMI remains uncertain. The stress induced by AMI is associated with several systemic metabolic changes, such as increased plasma concentrations of catecholamines, free fatty acids, glucose, glycerol, cortisol, and cyclic adenosine monophosphate (cAMP). 10, 11 The results of the present study showing a transient decrease in serum K levels during the first 2 days of hospitalization followed by stabilization confirmed the results of a previous study. 12 Sekiyama et al were the first to demonstrate a tight correlation of the degree of K dip with glucose levels in patients with acute coronary syndrome. 12 In addition, a longer hospitalization period as well as a higher incidence of myocardial infarction and higher peak of creatine kinase levels were observed in patients with a greater K dip during hospitalization. 12 Furthermore, the stimulation of the Na þ -K þ -ATPase pump by the increased catecholamines in AMI could result in intracellular K shift and therefore explain the hypokalemia in the acute phase of AMI. 10 Of note, such an early hypokalemic dip was not noticed in patients with AMI who were treated with b-blockers. 13 After taking into account the fact that drugs beyond b-blockers, such as aldosterone blockers, inhibitors of the renin-angiotensin system, and diuretics could significantly affect K fluctuations, a major limitation of the present study is the lack of data on concomitant treatment. In addition, the development and treatment of acute decompensated heart failure could explain fluctuations in serum K levels in the setting of an acute AMI. 1, 9 As mentioned above, several studies have reported that hypokalemia is associated with an increased risk of ventricular arrhythmias and poor prognosis in patients with AMI. 3, 4 The increased arrhythmogenicity of hypokalemia has been attributed to cellular hyperpolarization, increase in myocardial resting potential, automaticity, and excitability. 14, 15 Due to the fact that K influx affects cardiac repolarization, hypokalemia lengthens the action potential, increases QT dispersion, and predisposes patients to potential fatal arrhythmias. 14, 15 In addition, modest K depletion within the normal range has been reported to impair the contractile and relaxation responses to epinephrine, 14 whereas acute and chronic hypokalemia has been shown to sensitize the isolated heart to hypoxic injury. 16 However, recent treatment strategies for the management of AMI have reduced the risk of ventricular fibrillation >2-fold. 17 In this context, although Shiyovich et al did not report the causes of death in their study, others have shown no relationship between hypokalemia and the occurrence of malignant arrhythmias. 7, 8 Of note, these studies have demonstrated higher prevalence of comorbidities, such as chronic heart failure or hypertension, in patients with low serum K levels. 18 Therefore, the poor prognosis in patients with AMI and low serum K levels, as also noticed by Shiyovich et al, could be attributed to their comorbidities and not necessarily to the potential arrhythmogenicity of hypokalemia.
On the other hand, increased serum K levels have been associated with a larger scintigraphic infarct size and increased Killip class in patients with STEMI. 7 In addition, the kidneys are mostly responsible for K excretion and chronic kidney disease is a strong risk factor for increased mortality. 18, 19 Therefore, the increased mortality rates noticed in patients with AMI and high serum K levels could be explained by the underlying chronic renal failure. Furthermore, high serum K levels might reflect more comorbidities and severity in patients with AMI. For example, hyporeninemic hypoaldosteronism in diabetic patients or concomitant treatment affecting serum K levels in those with preexisting congestive heart failure could be related to high serum K levels. Thus, the association between poor prognosis in patients with AMI and high serum K levels could be attributed to the high prevalence of such comorbidities or the consumption of drugs, as noticed in most cohorts. 7, 8 Most previously published studies evaluated the impact of mean or admission serum K levels on the mortality in patients with AMI. Shiyovich et al, however, are the first to evaluate the extreme values of serum K, their combinations, and more importantly the fluctuations of K during hospitalization. The authors noticed that changes in serum K levels were a better prognostic marker than the absolute values. Thus, they correctly suggested that high serum K fluctuations could be related to high mortality rates due to the fact that they could reflect a more severe metabolic and hormonic situation with increased complications, such as acute heart failure and renal failure, or a more severe infarct.
In conclusion, an increasing number of observational reports consistently indicate a strong relationship between serum K levels and outcomes following AMI. Both reduced and more prominently increased serum K levels along with its fluctuations are associated with increased short-and long-term mortality or other negative outcomes in patients with AMI. Due to the several limitations of these observational studies and their methodological differences, it is not clear yet whether a causal relationship between serum K levels and cardiovascular outcomes exists or K is simply a marker of comorbidities associated with increased mortality (ie, diabetes, congestive heart failure, and chronic kidney disease). Nevertheless, after taking into consideration the growing evidence that serum K levels are also associated with mortality rates in the general population and in patients with other comorbidities apart from AMI, [20] [21] [22] the aforementioned findings should not be ignored. In this context, additional studies evaluating the mechanisms explaining the above associations and the impact of potential interventions in serum K levels on outcomes are needed. Until then, physicians should closely monitor serum K levels in patients with AMI, especially those with additional comorbidities, and they should consider intervening in cases of borderline and abnormal serum K values.
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